CAMP insider transaction filings
Camp4 Therapeutics Corp — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen CAMP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Schwab Andrew J. — Director | Sale (S): 45,147 @ $4.76 · Sale (S): 114,700 @ $4.54 · Sale (S): 32,018 @ $4.50 | EDGAR |
| 2026-08-19 | 4 | Tardiff Daniel — Chief Scientific Officer | Sale (S): 1,738 @ $4.76 | EDGAR |
| 2026-08-05 | 4 | 5AM Partners VI, LLC — 10% owner 5AM Ventures VI, L.P. — 10% owner 5AM Opportunities II (GP), LLC — 10% owner 5AM Opportunities II, L.P. — 10% owner 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner PARMAR KUSH — 10% owner | Purchase (P): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-05 | 4 | Schwab Andrew J. — Director | Grant/award (A): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-05 | 4 | Maricich Yuri — Chief Medical Officer | Purchase (P): 6,551 @ $1.65 | EDGAR |
| 2026-08-05 | 4 | Young Richard A — Director | Purchase (P): 16,378 @ $1.65 | EDGAR |
| 2026-08-05 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Purchase (P): 6,551 @ $1.65 | EDGAR |
| 2026-08-05 | 4 | Gold Kelly — Chief Financial Officer | Purchase (P): 6,551 @ $1.65 | EDGAR |
| 2026-06-12 | 4 | Stewart Murray — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Schwab Andrew J. — Director, 10% owner | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Nashat Amir — Director, 10% owner | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Young Richard A — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Holtzman Steven H — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | WILLIAMS DOUGLAS E — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Tardiff Daniel — Chief Scientific Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Gold Kelly — Chief Financial Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Grant/award (A): 580,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Maricich Yuri — Chief Medical Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | MacLean Michael F — Director | Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Tardiff Daniel — Chief Scientific Officer | Grant/award (A): 145,500 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Gold Kelly — Chief Financial Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Grant/award (A): 425,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Maricich Yuri — Chief Medical Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2025-09-15 | 4 | 5AM Partners VI, LLC — 10% owner 5AM Ventures VI, L.P. — 10% owner 5AM Opportunities II (GP), LLC — 10% owner 5AM Opportunities II, L.P. — 10% owner 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner PARMAR KUSH — 10% owner | Purchase (P): 2,941,176 @ $1.53 | EDGAR |
| 2025-09-15 | 4 | Schwab Andrew J. — Director, 10% owner | Grant/award (A): 2,941,176 @ $1.53 | EDGAR |
| 2025-09-11 | 4 | Gold Kelly — Chief Financial Officer | Purchase (P): 6,060 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Purchase (P): 6,060 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Maricich Yuri — Chief Medical Officer | Purchase (P): 6,060 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Nashat Amir — Director, 10% owner | Purchase (P): 1,221,721 @ $1.53 · Purchase (P): 85,468 @ $1.53 | EDGAR |
| 2025-09-11 | 4 | Young Richard A — Director | Purchase (P): 15,151 @ $1.65 | EDGAR |
| 2025-09-11 | 4 | Polaris Management Co. VII, L.L.C. — 10% owner Polaris Partners VII, L.P. — 10% owner Polaris Entrepreneurs' Fund VII, L.P. — 10% owner Polaris Partners X, L.P. — 10% owner Polaris Partners GP X, L.L.C. — 10% owner SCHULMAN AMY W — 10% owner Chee Brian — 10% owner | Purchase (P): 1,221,721 @ $1.53 · Purchase (P): 85,468 @ $1.53 | EDGAR |
| 2025-06-27 | 4 | Boylan James P — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Thadhani Ravi I. — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Ragan Paula — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Schwab Andrew J. — Director, 10% owner | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Nashat Amir — Director, 10% owner | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Young Richard A — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Higgins Michael J — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Holtzman Steven H — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Bumcrot David — Chief Scientific Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Maricich Yuri — Chief Medical Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Gold Kelly — Chief Financial Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Mandel-Brehm Josh — Chief Executive Officer, Director | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Stewart Murray — Director | Grant/award (A): 17,787 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | WILLIAMS DOUGLAS E — Director | Grant/award (A): 17,787 (derivative) @ $0 | EDGAR |
Recent 8-K events — Camp4 Therapeutics Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-05 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CAMP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →